Juno announces FDA clearance of IND for JCAR015 adult patients with r/r ALL
Juno announced the FDA cleared the Company's investigational NDA for JCAR015 for treatment of adult patients with relapsed/refractory acute lymphoblastic leukemia. The IND enables Juno to initiate a multi-center, pivotal Phase 2 trial evaluating JCAR015 in patients with r/r ALL. July 30, 2015